Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. on February 3, 2011. The filing discloses the entry into a material definitive agreement involving a second amendment to a Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and its affiliate, Hoffman-La Roche Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the legal amendment of a collaboration agreement rather than financial performance data.
Material Changes
- Agreement Amendment: On February 3, 2011, Synta and Roche executed a second amendment to their original 2008 Collaboration and License Agreement, effective January 1, 2011.
- License Extension: The amendment extends Roche's license to perform research on certain specified compounds targeting calcium release-activated calcium modulator channels until June 30, 2011.
- Asset Return: The amendment mandates the return to Synta of certain compounds that were previously licensed to Roche during the initial research term, which concluded on December 31, 2010.
Outlook, Risks, and Management Commentary
The collaboration focuses on the discovery, development, and commercialization of compounds for the treatment of inflammatory diseases. Management intends to file the full text of the Amendment as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending March 31, 2011. The filing does not explicitly detail new risks or contingencies beyond the operational changes to the existing agreement.
Investor Verification Checklist
- Verify the specific list of compounds being returned to Synta by reviewing the full Amendment text in the upcoming Form 10-Q.
- Confirm the financial implications of the license extension and asset return, as no monetary values are disclosed in this 8-K.
- Monitor the progress of the research on calcium release-activated calcium modulator channels through the new June 30, 2011 deadline.